Login
$ELTX
$1.48 -$0.02 (1.33%) Live

$ELTX SEC Filings

Filed On Filing
13 Nov 2026 8-K: Submission of Matters to a Vote of Security Holders

On November 12, 2026, Elicio Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on two proposals, each of wh...

05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and pa...

09 Oct 2026 Proxy statement: annual meeting on November 12, 2026
14 Sep 2026 8-K: Shareholder Director Nominations; Other Events

To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K “Notice of Annual Meeting” is incorporated by reference into this Item 5.08.

02 Sep 2026 Form 4: Adams Julian, Director

Granted 21,750 Stock Option (Right to Buy)

02 Sep 2026 Form 4: Ashe Carol Gail, Director

Granted 21,750 Stock Option (Right to Buy)

02 Sep 2026 Form 4: Chudnovsky Yekaterina, Director

Granted 21,750 Stock Option (Right to Buy)

02 Sep 2026 Form 4: Nissenson Allen, Director

Granted 21,750 Stock Option (Right to Buy)

02 Sep 2026 Form 4: Ruffolo Robert R, Director

Granted 21,750 Stock Option (Right to Buy)

02 Sep 2026 Form 4: Wilson Karen J, Director

Granted 21,750 Stock Option (Right to Buy)

02 Sep 2026 Form 4: Venkatesan Jay, Director

Granted 21,750 Stock Option (Right to Buy)

13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS sm...

17 Jul 2026 Form 4: Haqq Christopher, See Remarks

Granted 64,643 Stock Option (Right to Buy)

17 Jul 2026 Form 4: DeMuth Peter, Chief Scientific Officer

Granted 52,832 Stock Option (Right to Buy)

17 Jul 2026 Form 4: Shah Preetam, See Remarks

Granted 60,833 Stock Option (Right to Buy)

17 Jul 2026 Form 4: Connelly Robert, Director

Granted 186,944 Stock Option (Right to Buy)

16 Jul 2026 SCHEDULE 13G
08 Jul 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support